Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05105308 · ClinicalTrials.gov registry record · NA
Chompions! A Treatment Study for Childhood Avoidant/Restrictive Food Intake Disorder (ARFID)
A NA study of ARFID and Picky Eating, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 203
- Enrollment target
- 1
- Study location
NCT05105308: Completed NA study of ARFID and Picky Eating, sponsored by Duke University.
NCT05105308 is a NA study of ARFID and Picky Eating that has completed, run by Duke University. The registered enrollment target is 203 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05105308, a NA study of ARFID and Picky Eating, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 203 participants
- Enrollment target
- 1
- Study location
Study Summary
Avoidant Restrictive Food Intake Disorder (ARFID) is a disorder that affects toddlers, children, adolescents, and adults. Individuals with ARFID are not able to consume an adequate amount or variety of food to a degree that it affects their mental and/or physical health. ARFID often begins in early childhood so it is important to treat children in early in life as possible to prevent any negative consequences of poor nutrition. There are currently no treatments for young children with ARFID. The investigators have developed two different study programs and the purpose of this study is to test them out and see if they help children with ARFID and to learn more about how these study programs work.
Primary Outcome
The 17-item PARDI measures symptoms including body mass index, diet quality, dependence on supplement use for sufficient calories, and psychosocial impairment. Each item assesses a symptom on a 0 - 6 scale, with scores above 4 indicating that it is a clinically severe symptom.
Conditions Studied
Interventions
- BEHAVIORAL Family Assisted Diet (FAD)
- BEHAVIORAL Feeling and Body Investigator_ARFID Division (FBI-ARFID)
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2025-09-29 |
| Phase | NA |
What the finished NCT05105308 record still lists
NCT05105308 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with ARFID appearing as the primary indexed condition, and to 2 interventions - of which Family Assisted Diet (FAD) is the first listed.
NCT05105308 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05105308 about?
NCT05105308 is a clinical study titled "Chompions! A Treatment Study for Childhood Avoidant/Restrictive Food Intake Disorder (ARFID)". Avoidant Restrictive Food Intake Disorder (ARFID) is a disorder that affects toddlers, children, adolescents, and adults. Individuals with ARFID are not able to consume an adequate amount or variety of food to a degree that it affects their mental and/or physical health. ARFID often begins in early ...
What is the current status of trial NCT05105308?
This trial is currently completed. It is a NA study. The enrollment target is 203 participants. The study started on 2022-02-10. Estimated completion is 2025-09-29.
What conditions does trial NCT05105308 study?
This clinical trial studies the following conditions: ARFID, Picky Eating, Eating Disorders in Children.
What interventions are being tested in trial NCT05105308?
The interventions under investigation include: Family Assisted Diet (FAD) (BEHAVIORAL), Feeling and Body Investigator_ARFID Division (FBI-ARFID) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05105308?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05105308 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ARFID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05105308's enrollment target sits among peer trials
203 504th of 2000 higher than 1,496 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI